Kyverna Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
KYTX$5.08-1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations and Comprehensive Income (Loss)
(in thousands, except share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Operating expenses | ||||
| Research and development | $29,193 | $13,644 | $78,990 | $32,760 |
| General and administrative | 9,577 | 2,638 | 22,573 | 8,269 |
| Total operating expenses | 38,770 | 16,282 | 101,563 | 41,029 |
| Loss from operations | (38,770) | (16,282) | (101,563) | (41,029) |
| Interest income | 4,355 | 880 | 11,784 | 1,493 |
| Interest expense | (32) | (50) | (115) | (140) |
| Other expense, net | (45) | (13) | (94) | (23) |
| Total other income, net | 4,278 | 817 | 11,575 | 1,330 |
| Net loss | (34,492) | (15,465) | (89,988) | (39,699) |
| Other comprehensive income | ||||
| Unrealized gain on available-for-sale marketable securities, net | 190 | 5 | 149 | 31 |
| Total other comprehensive income | 190 | 5 | 149 | 31 |
| Net loss and other comprehensive income (loss) | $(34,302) | $(15,460) | $(89,839) | $(39,668) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.80) | $(23.27) | $(2.45) | $(62.75) |
| Weighted-average shares of common stock outstanding, basic and diluted | 43,155,858 | 664,656 | 36,702,183 | 632,624 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.